152 related articles for article (PubMed ID: 36871090)
1. Heterodimerization of cholecystokinin 1 and cholecystokinin 2 receptors in gallbladder cancer: a new mechanism for carcinogenesis.
Nigam J; Kazmi HR; Khare L; Srivastava M; Chandra A
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7069-7078. PubMed ID: 36871090
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of cholesterol absorption is a mechanism for cholecystokinin-induced hypercholesterolemia.
Zhou L; Yang H; Okoro EU; Guo Z
J Biol Chem; 2014 May; 289(19):12989-99. PubMed ID: 24692543
[TBL] [Abstract][Full Text] [Related]
3. CCK1 receptor is involved in the regulation of protein lysine acetylation in GBC-SD cells and gallbladder carcinoma.
Wu W; Ouyang B; Lu Z; Liu H; Tan Y; Cui P
Ir J Med Sci; 2017 Nov; 186(4):883-888. PubMed ID: 28470351
[TBL] [Abstract][Full Text] [Related]
4. Expression of cholecystokinin receptors in colon cancer and the clinical correlation in Taiwan.
Huang BP; Lin CH; Chen YC; Kao SH
Tumour Biol; 2016 Apr; 37(4):4579-84. PubMed ID: 26508021
[TBL] [Abstract][Full Text] [Related]
5. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.
Berna MJ; Tapia JA; Sancho V; Jensen RT
Curr Opin Pharmacol; 2007 Dec; 7(6):583-92. PubMed ID: 17997137
[TBL] [Abstract][Full Text] [Related]
6. Genetic, pharmacological and functional analysis of cholecystokinin-1 and cholecystokinin-2 receptor polymorphism in type 2 diabetes and obese patients.
Marchal-Victorion S; Vionnet N; Escrieut C; Dematos F; Dina C; Dufresne M; Vaysse N; Pradayrol L; Froguel P; Fourmy D
Pharmacogenetics; 2002 Jan; 12(1):23-30. PubMed ID: 11773861
[TBL] [Abstract][Full Text] [Related]
7. Cholecystokinin type 2 receptor in colorectal cancer: diagnostic and therapeutic target.
Chang J; Liu ZS; Song DF; Li M; Zhang S; Zhao K; Guan YT; Ren HL; Li YS; Zhou Y; Liu XL; Lu SY; Hu P
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2205-2217. PubMed ID: 32488497
[TBL] [Abstract][Full Text] [Related]
8. Mechanism for Src activation by the CCK2 receptor: Patho-physiological functions of this receptor in pancreas.
Ferrand A; Vatinel S; Kowalski-Chauvel A; Bertrand C; Escrieut C; Fourmy D; Dufresne M; Seva C
World J Gastroenterol; 2006 Jul; 12(28):4498-503. PubMed ID: 16874861
[TBL] [Abstract][Full Text] [Related]
9. Expression of cholecystokinin, gastrin, and their receptors in the mouse cornea.
Gonzalez-Coto AF; Alonso-Ron C; Alcalde I; Gallar J; Meana Á; Merayo-Lloves J; Belmonte C
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1965-75. PubMed ID: 24576871
[TBL] [Abstract][Full Text] [Related]
10. An ITIM-like motif within the CCK2 receptor sequence required for interaction with SHP-2 and the activation of the AKT pathway.
Vatinel S; Ferrand A; Lopez F; Kowalski-Chauvel A; Estève JP; Fourmy D; Dufresne M; Seva C
Biochim Biophys Acta; 2006 Oct; 1763(10):1098-107. PubMed ID: 16963136
[TBL] [Abstract][Full Text] [Related]
11. miR-4461 inhibits the progression of Gallbladder carcinoma via regulating EGFR/AKT signaling.
Yan X; Yang P; Liu H; Zhao Y; Wu Z; Zhang B
Cell Cycle; 2022 Jun; 21(11):1166-1177. PubMed ID: 35196196
[TBL] [Abstract][Full Text] [Related]
12. Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice.
Clerc P; Coll Constans MG; Lulka H; Broussaud S; Guigné C; Leung-Theung-Long S; Perrin C; Knauf C; Carpéné C; Pénicaud L; Seva C; Burcelin R; Valet P; Fourmy D; Dufresne M
Endocrinology; 2007 Mar; 148(3):1039-49. PubMed ID: 17122076
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.
Desai AJ; Lam PC; Orry A; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
J Med Chem; 2015 Dec; 58(24):9562-77. PubMed ID: 26654202
[TBL] [Abstract][Full Text] [Related]
14. Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies.
Galés C; Poirot M; Taillefer J; Maigret B; Martinez J; Moroder L; Escrieut C; Pradayrol L; Fourmy D; Silvente-Poirot S
Mol Pharmacol; 2003 May; 63(5):973-82. PubMed ID: 12695525
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase.
Yu HG; Tong SL; Ding YM; Ding J; Fang XM; Zhang XF; Liu ZJ; Zhou YH; Liu QS; Luo HS; Yu JP
Int J Cancer; 2006 Dec; 119(12):2724-32. PubMed ID: 16998832
[TBL] [Abstract][Full Text] [Related]
16. Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis.
Quattrone A; Dewaele B; Wozniak A; Bauters M; Vanspauwen V; Floris G; Schöffski P; Chibon F; Coindre JM; Sciot R; Debiec-Rychter M
J Pathol; 2012 Dec; 228(4):565-74. PubMed ID: 22786615
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
